uniQure Plunges 65% as 48-Month Huntington's Gene Therapy Data Misses Key Stat

3-line summary

• uniQure shares plunged 65% after its 48-month Huntington's disease gene therapy data missed a key statistic, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.